Advanced, Humanized and Cell-based
Modular Platform for Epilepsy Modelling in vitro
MEMO platform is devoted to solve following challenges
Finding novel approaches to discover truly innovative anti-seizure medicatons
Accomplish CNS safety testing for seizure liability early enough during drug discovery
Advancing tools to reveal disease mechanisms of epilepsies
Gas supply chamber
MEMO is an advanced platform technology innovated in a project owned by Tampere University, Finland. MEMO platform bases on the strong and impactful neuroscientific and microfabrication technology backgrounds of NeuroGroup (led by Adj. Prof Susanna Narkilahti) and Micro- and Nanosystems Research group (led by Prof Pasi Kallio).
MEMO project is a Research to Business project, aiming to the commercialization of research results and is funded by Business Finland.
MEMO project team
Our team has over 15 years of experience in combining neuroscience and engineering technologies. We have excellent hands-on expertise of human pluripotent stem cells, neuronal cultures, microfluidics, microelectrode arrays and data analysis. MEMO project has a comprehensive steering group from the fields of business and engineering technologies as well as epilepsy and drug R&D research.
Adj. Prof. Neuroscience Specialist, stem cells, in vitro models
MSc, Business Champion, Cell Technology Scientist
PhD, Senior Expert, Neuroscience, Drug development
Prof. Engineering Specialist, Nano- and microfluidic systems
MSc, Microfluidic and Microfabrication Specialist
PhD, Sensors and Electronics Specialist, Microfabrication